Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The employee’s equity awards vest over time and require continued employment through each applicable vesting date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spero Therapeutics (Nasdaq: SPRO) granted equity awards to a new employee on November 2, 2026, as an employment inducement. The Compensation Committee approved 217,000 restricted stock units (RSUs) and 434,000 stock options under the amended 2019 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest 25% on the first anniversary of the vesting start date, with the remainder vesting in 36 equal monthly installments thereafter. The RSUs vest in four equal annual installments beginning on that first anniversary. Both awards require continued employment through the applicable vesting dates.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.217,000 RSUs and 434,000 stock options create potential dilution as the employee’s awards vest.
Key Figures
- Restricted stock unit awards
- 217,000 awards
- Inducement grant to a new employee
- Stock options
- 434,000 options
- Inducement grant to a new employee
- Initial option vesting
- 25%
- On the first anniversary of the vesting start date
- Remaining option vesting
- 36 equal monthly installments
- After the initial vesting on the first anniversary
- RSU vesting
- 4 equal annual installments
- Beginning on the first anniversary of the vesting start date
Historical Context
-
Prior award under the same plan included 233,000 RSUs and 323,000 options with similar vesting terms.
-
Prior award under the same plan included 102,000 RSUs and 67,600 options with similar vesting terms.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock unit financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that the Compensation Committee of Spero’s Board of Directors approved a grant, made on November 2, 2026, of an aggregate of 217,000 restricted stock unit awards (RSUs) and 434,000 stock options to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employee in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as a material inducement for such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The shares underlying the options vest as to
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com
Media Inquiries: media@sperotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Spero Therapeutics grant to its new employee?
Spero granted 217,000 RSUs and 434,000 stock options to a new employee on November 2, 2026. The awards were employment inducements under the amended 2019 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Who is eligible for Spero Therapeutics’ 2019 Inducement Plan?
The plan is used exclusively for equity awards to individuals who were not previously Spero employees, or who return after a bona fide period of non-employment. The awards must serve as a material inducement to enter employment with Spero.